FGF23 and X-linked hypophosphatemia: Liu et al. [95] treated mice suffering from XLH with daily 1,25(OH)2D3 repletion, FGF23 antibodies or biweekly high-dose of 1,25(OH)2D3 from d2 to d75 without supplemental phosphate to establish if 1,25(OH)2D3 or blocking FGF23 activity could improve the skeletal phenotype without phosphate supplementation.